Pfizer is committed to developing novel therapies that improve the lives of patients with ophthalmic diseases. Our in-line medicines in this area include Xalatan® (latanoprost ophthalmic solution), Xalacom® (latanoprost and timolol), and Macugen® (pegaptanib injection). Within Pfizer an Ophthalmology forum exists to align several research units under WRD leadership. WRD established the Ophthalmology External Research Unit (OERU) to lead this effort. The OERU utilizes a virtual biotech model to build its portfolio through shared-risk partnerships leveraging the combined scientific, development, and commercial expertise of Pfizer and its partners. The OERU's alliance with Lpath, Inc. to develop and commercialize iSONEP®, which is being evaluated for the treatment of wet age-related macular degeneration and other ophthalmology disorders, is an excellent example of this innovative collaborative approach. The other units focusing on Ophthalmology within WRD are Rinat and Neusentis. Rinat focuses on a monoclonal antibody approach for the treatment of ophthalmic disease. Within this unit RN6G, a monoclonal antibody targeting amyloid beta peptides, is being tested in a clinical trial for use in dry AMD and Geographic Atrophy. The Neusentis unit within WRD is at the forefront of stem cell technology and is studying its use for wet AMD.

WRD is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

  • Retinal Diseases
    • Wet AMD, Dry AMD
    • Diabetic Retinopathy
    • Diabetic Macular Edema
    • Geographic Atrophy
    • Retinal Venous Occlusive Disease
  • Rare ophthalmic diseases, including Retinitis Pigmentosa
    • Agents promoting cone survival
    • Agents targeting cause of defect
    • Rescue approaches to protein misfolding
  • Uveitis (Posterior)
  • Primary open angle glaucoma
  • Dry Eye

Specific areas of interest include:

  • Retinal Diseases
    • Anti-angiogenic approaches different from VEGF targeting
    • Novel agents with new MOAs
    • Anti-inflammatory agents
    • Drusen-targeting approaches
  • Primary open angle glaucoma
    • Neuroprotective agents, going beyond IOP lowering alone
  • Dry Eye
    • Disease-modifying agents
    • Combination of anti-inflammatory and lubricating activity
  • Ophthalmic drug delivery
    • IVT injection-sparing approaches
    • Extended activity approaches
    • Sustained delivery approaches
  • Ophthalmic devices for treatment of Retinal Diseases, Glaucoma, Dry Eye, or rare ophthalmic diseases (e.g., electronic implants)